<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04152577</url>
  </required_header>
  <id_info>
    <org_study_id>ShangdongPH</org_study_id>
    <nct_id>NCT04152577</nct_id>
  </id_info>
  <brief_title>R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL</brief_title>
  <official_title>Lenalidomide, Rituximab and Combination Chemotherapy Versus Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Highly Aggressive Non-Hodgkin B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Provincial Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study，lenalidomide was added in the first-line treatment in the newly diagnosed&#xD;
      highly invasively non-Hodgkin B-cell lymphoma. The R2-CHOP/R2-EPOCH etc was applied compared&#xD;
      with the classical R-CHOP/R-EPOCH etc. The investigators tried to explore a more effective&#xD;
      and safe treatment regimen for patients with high-risk B-cell lymphoma to improve the&#xD;
      patient's poor prognosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lymphoma has become one of the top ten malignant tumors, of which non-Hodgkin's B-cell&#xD;
      lymphoma accounts for the majority. As the classic first-line treatment, the emergence of the&#xD;
      R-CHOP program has resulted in clinical cures for more than 1/2 of patients with B-cell&#xD;
      lymphoma. But for patients with highly aggressively B cell lymphoma, most of them still&#xD;
      suffer from disease recurrences due to R-CHOP treatment alone.&#xD;
&#xD;
      In recent years, with the emergence of various new drugs, many researchers have tried to add&#xD;
      new drugs to the classic R-CHOP program as a first-line treatment for non-Hodgkin B-cell&#xD;
      lymphoma. As a new type of immunomodulator, lenalidomide was first approved for the treatment&#xD;
      of multiple myeloma. In recent years, its role in refractory and relapsed B-cell lymphoma has&#xD;
      gradually been recognized.&#xD;
&#xD;
      In 2015, Nowakowski et al. published a clinical study of 64 patients with diffuse large&#xD;
      B-cell lymphoma who used R2-CHOP in first-line therapy. It was found that R2-CHOP does not&#xD;
      improve R-CHOP in patients with GCB. The effective rate of treatment and the 2-year survival&#xD;
      rate of patients, but for patients with non-GCB type DLBCL with poor prognosis, the addition&#xD;
      of lenalidomide can greatly improve the remission rate of the disease and improve the poor&#xD;
      prognosis of patients.&#xD;
&#xD;
      So, the investigators initiate this study to evaluate the efficacy of R2-CHOP/R2-EPOCH etc in&#xD;
      newly diagnosed highly invasively non-Hodgkin B-cell lymphoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate after 3 cycles</measure>
    <time_frame>at the end of 3 cycles( each cycle is 21 days)</time_frame>
    <description>Percentage of patients with complete remission （CR）or partial remission （PR）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate after 6 cycles</measure>
    <time_frame>at the end of 6 cycles( each cycle is 21 days)</time_frame>
    <description>Percentage of patients with complete remission （CR）or partial remission （PR）</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival（PFS）</measure>
    <time_frame>2 years</time_frame>
    <description>Time from enrollment to tumor progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival（OS）</measure>
    <time_frame>2 years</time_frame>
    <description>Time from enrollment to death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Lymphoma, B-Cell</condition>
  <arm_group>
    <arm_group_label>R2-combination chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R2-CHOP/CHOPE/DA-EPOCH/HD MTX&#xD;
R2-CHOP :&#xD;
lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5&#xD;
R2-DA-EPOCH:&#xD;
lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;&#xD;
R2-HD MTX:&#xD;
lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-combination chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>R-CHOP/CHOPE/DA-EPOCH/HD MTX&#xD;
R-CHOP :&#xD;
Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5&#xD;
R-DA-EPOCH:&#xD;
Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;&#xD;
R-HD MTX:&#xD;
Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R2-combination chemotherapy</intervention_name>
    <description>R2-CHOP/CHOPE/DA-EPOCH/HD MTX&#xD;
R2-CHOP :&#xD;
lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5&#xD;
R2-DA-EPOCH:&#xD;
lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;&#xD;
R2-HD MTX:&#xD;
lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1</description>
    <arm_group_label>R2-combination chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-combination chemotherapy</intervention_name>
    <description>R-CHOP/CHOPE/DA-EPOCH/HD MTX&#xD;
R-CHOP :&#xD;
Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5&#xD;
R-DA-EPOCH:&#xD;
Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;&#xD;
R-HD MTX:&#xD;
Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1</description>
    <arm_group_label>R-combination chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Newly diagnosed highly aggressively B-Cell Non-Hodgkin's lymphoma (NHL) confirmed by&#xD;
             histopathology&#xD;
&#xD;
          2. The patient has at least ≥1 measurable tumor lesion with a diameter &gt;1.5 cm;&#xD;
&#xD;
          3. The patient has not undergone systemic chemotherapy or immunotherapy before;&#xD;
&#xD;
          4. ECOG score ≤ 2 points;&#xD;
&#xD;
          5. Liver and kidney function meets the following conditions: creatinine clearance rate ≥&#xD;
             30ml / min, total bilirubin, AST and ALT ≤ 2.5 × ULN;&#xD;
&#xD;
          6. No history of malignant tumors within 5 years, except for cured carcinomas in situ&#xD;
             such as basal cell carcinoma of the skin, cervical cancer, breast cancer, prostate&#xD;
             cancer, etc.;&#xD;
&#xD;
          7. agree to take contraceptive measures during the trial period and within 3 months after&#xD;
             the end of the trial;&#xD;
&#xD;
          8. Patients volunteered to participate in the study and signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious cardiovascular and other important organs and blood, endocrine system lesions,&#xD;
             and other history of malignant tumors;&#xD;
&#xD;
          2. Severe mental illness;&#xD;
&#xD;
          3. Pregnant or lactating women and men or women who intend to conceive in the near&#xD;
             future;&#xD;
&#xD;
          4. The expected survival time is less than 6 months;&#xD;
&#xD;
          5. HBV, HCV or HIV infection or seropositive;&#xD;
&#xD;
          6. there are active infections;&#xD;
&#xD;
          7. Allergies or allergies to rituximab;&#xD;
&#xD;
          8. Compliance or poor follow-up;&#xD;
&#xD;
          9. Other circumstances that the investigator believes are not suitable for inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Wang, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong Provincial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xin Wang, MD,PhD</last_name>
    <phone>+86-531-68778331</phone>
    <email>xinw8331@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiao Lv, MD,PhD</last_name>
    <phone>+86-531-68778331</phone>
    <email>lvxiao8377@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Hematology, Provincial Hospital Affiliated to Shandong University</name>
      <address>
        <city>Jin'an</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Wang, MD, PHD</last_name>
      <phone>86-531-68778331</phone>
      <email>xinw8331@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiao Lv, MD,PHD</last_name>
      <phone>86-531-68778331</phone>
      <email>lvxiao8377@sina.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 27, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Provincial Hospital</investigator_affiliation>
    <investigator_full_name>Wang Xin</investigator_full_name>
    <investigator_title>Director of Hematology Department</investigator_title>
  </responsible_party>
  <keyword>Lenalidomide，rituximab，chemotherapy，highly aggressive B-NHL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

